Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Integra Lifesciences Holdings (IART) EBT Margin (2016 - 2026)

Integra Lifesciences Holdings' EBT Margin history spans 17 years, with the latest figure at 0.99% for Q4 2025.

  • On a quarterly basis, EBT Margin fell 410.0% to 0.99% in Q4 2025 year-over-year; TTM through Dec 2025 was 34.46%, a 3333.0% decrease, with the full-year FY2025 number at 34.46%, down 3333.0% from a year prior.
  • EBT Margin hit 0.99% in Q4 2025 for Integra Lifesciences Holdings, up from 1.7% in the prior quarter.
  • Over the last five years, EBT Margin for IART hit a ceiling of 18.68% in Q1 2021 and a floor of 127.75% in Q2 2025.
  • Historically, EBT Margin has averaged 0.49% across 5 years, with a median of 6.18% in 2023.
  • Biggest five-year swings in EBT Margin: skyrocketed 1546bps in 2021 and later tumbled -12412bps in 2025.
  • Tracing IART's EBT Margin over 5 years: stood at 12.77% in 2021, then increased by 26bps to 16.13% in 2022, then crashed by -55bps to 7.27% in 2023, then dropped by -30bps to 5.09% in 2024, then plummeted by -81bps to 0.99% in 2025.
  • Business Quant data shows EBT Margin for IART at 0.99% in Q4 2025, 1.7% in Q3 2025, and 127.75% in Q2 2025.